Navigation Links
Major clinical study rejects cancer safety fears of most common heartburn treatment
Date:9/9/2009

Fears about the cancer causing effects of the second most prescribed group of drugs in the Western world have been put to rest, following the largest ever study into their use.

'Proton pump inhibitors' (PPI) are the most commonly used treatment for chronic acid reflux, or 'heartburn', a painful burning sensation in the chest, neck and throat which is experienced by almost a third of people in developed countries.

Regular and prolonged heartburn is known to cause 'benign oesophagitis', a reversible inflammation of the gullet. However if left untreated a condition called Barrett's Oesophagus (BE) occurs in around 10 per cent of sufferers, which can in turn develop into a potentially fatal cancer called oesophageal adenocarcinoma.

BE is twice as common in the UK as it is in the USA, and oesophageal cancer rates in the UK are the highest in the world; up to four times more common than in other European countries.

Despite their excellent safety record, it was unclear if long-term use of PPIs to reduce the discomfort of heartburn could increase the risk of developing either BE or the spread of the associated cancer.

New research carried out at Queen Mary, University of London and Leicester Royal Infirmary, has given the most conclusive evidence yet that this is not the case. The work is published in the peer reviewed journal Gut.

Professor Janusz Jankowski, who co-authored the study, said: "This is one of the most detailed studies investigating both the laboratory and clinical side of proton pump inhibitor drugs. As a consequence we are now better able to inform patients of the good benefit/risk ratio of this commonly prescribed therapy."

Tests carried out during the two-year study looked at tissue sampled from the oesophagus lining of ninety volunteers, each of whom were given PPI drugs at either a high or low dosage. Researchers found there was no difference in the rate at which BE developed, neither was there a change in the number of precancerous cells in either group.

While there had also been fears about how the treatments might affect people already suffering from BE, the study also showed that there was no evidence that this led to any worsening of the condition or any extra incidences of cancer.

BE is marked by changes in the cells of the oesophagus lining (squamous epithelium) that makes them more like the cells of the intestines (columnar epithelium). As well as increasing the risk of oesophageal cancer, the condition narrows the oesophagus and patients can experience pain whilst swallowing. The chance of cancer developing is proportional to the length of BE.

PPIs work by blocking the action of gastrin, a hormone that controls acid levels in the stomach, and is known to increase the normal movement of cells in the gastro-intestinal tract. Since PPI therapy increases the levels of gastrin in the body, it had been thought this could cause expansion of BE affected tissue, but this was not found to be the case: the scientists observed neither expansion or contraction of the abnormal tissue. This is concordant with current UK practice, where PPI therapy is currently only licensed to treat heartburn and 'oesophagitis' but not BE.


'/>"/>

Contact: Simon Levey
s.levey@qmul.ac.uk
44-207-882-5404
Queen Mary, University of London
Source:Eurekalert

Related medicine news :

1. First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain
2. NIH awards major grant to Chicago-based consortium to create center for AIDS research
3. Cancer Community Alarmed at CMS Policy Lumping Life-Saving Cancer Therapy With Diagnostic Testing For Major Funding Cuts
4. Major League Baseball Pitchers John Smoltz and Derek Lowe Help Raise Awareness Throughout Prostate Cancer Awareness Month
5. In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company
6. In Final Hour Prior to Litigation, Angel MedFlights Air Ambulance Team Overturns Decision by Major Insurance Company
7. Red Cross Survey Finds Overwhelming Majority of Public Taking Steps against H1N1 Flu Virus
8. Gene variation is major genetic determinant of psoriasis
9. Viral Genetics Completes Second Major Debt Conversion
10. IU national survey finds majority of Americans believe myths about health care reform
11. Prostate Net Announces: Major Medical Education Initiative for Patients, Caregivers and Healthcare Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September 20, 2017 , ... ... date of the much-anticipated fall event , Look Awesome This Autumn with ... personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that Clear Global ... support services market) has entered into an agreement on September 1, 2017 with ... PGSD is the first private Dental School to launch an online, accredited Post ...
(Date:9/20/2017)... ... , ... Compliancy Group is proud to announce that its ... another long-time client pass their Department of Health and Human Services (HHS) Office ... to the help of the Compliancy Group's Audit Response Program™, not a single ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods ... market impact in 27 different categories. Nopavera Plus was named to the ... be announced at SupplySide West 2017 during presentations at SupplySide Central on Sept. 27 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: